BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.
Cervical cancer is a rare form of gynecologic cancer. Learn about cervical cancer signs, symptoms, causes and treatments from the OSUCCC – James.
An abstract is unavailable.
The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
The SGO Winter Meeting connects researchers and surgeons at all career stages through scientific sessions, bold discussions, posters, and networking events, while offering winter and…
Phospho-dependent degradation mediated by cullin 3 with ARMC5 adaptor eliminates defective transcription complex lacking SPT5.
A new study found that getting a glass of milk’s worth of calcium per day, whether or not it comes from dairy, can lower colorectal…
An abstract is unavailable.